Uninterrupted treatment with dabigatran, a non-vitamin K antagonist oral anticoagulant (NOACs), before, during and after ablation to treat atrial fibrillation significantly reduced the incidence of major bleeding events compared with uninterrupted use of the more established anticoagulant warfarin.